Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment?

American Journal of Hematology

Volumn 83, Issue 8, 2008, Pages 673-675

  Garcia Rodriguez, Maria J ^a   Canales, Miguel A ^a,b   Hernandez Maraver, Dolores ^a   Hernandez Navarro, Fernando ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE; VORICONAZOLE;

ACUTE PANCREATITIS; ADULT; AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CAUSE OF DEATH; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; GUANINE; HEPATITIS B; HUMANS; LYMPHOMA, B-CELL; MIDDLE AGED; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 49149111443     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21214     Document Type: Article

References (20)

1. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21:67-72.
2. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
3. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and its prevention. Clin Gastroenterol Hepatol 2006;4:1076-1081.
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
5. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
6. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60.
7. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-1089.
8. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-191.
9. Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005;19:1840-1841.
10. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-724.
11. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
12. Yamagata M, Murohisa T, Tsuchida K, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007;48(2):431-433.
13. Firpi RJ, Nelson DR. Viral hepatitis: Manifestations and management strategy. Hematol Am Soc Hematol Educ Program 2006:375-380.
14. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68:105-112.
15. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006;45:747-748.
16. Hanbali A, Khaled Y, Ajrouche H, et al. Incidence of hepatitis B reactivation in association with rituximab therapy. Blood 2006;108:2766 (abstract).
17. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
18. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology 2004;39:857-861.
19. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005;55: 828-831.
20. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.